Mechanistic insights into VSIR-mediated AXL regulation and gastric cancer proliferation

The Lupus Susceptibility Locus Sgp3 Encodes the Suppressor of Endogenous Retrovirus Expression SNERV

10.1016/j.immuni.2018.12.022 · doi-reference

Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors

10.1021/acs.jmedchem.2c01346 · doi-reference

Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models

10.1158/1535-7163.mct-19-0873 · doi-reference

AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients

10.1038/npjbcancer.2016.33 · doi-reference

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

10.1038/s41591-023-02465-7 · doi-reference

VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy

10.1016/j.it.2020.12.008 · doi-reference

Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment

10.3390/cancers12071850 · doi-reference

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

10.1038/s41467-018-08074-0 · doi-reference

A dual MET/AXL small-molecule inhibitor exerts efficacy against gastric carcinoma through killing cancer cells as well as modulating tumor microenvironment

10.1002/mco2.11 · doi-reference

Association Between Phosphorylated AXL Expression and Survival in Patients with Gastric Cancer

10.3390/jcm13226694 · doi-reference

Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma

10.1007/s10120-020-01066-4 · doi-reference

The Receptor Tyrosine Kinase Axl in (Advanced) Gastric Cancer-From Pathophysiology to Therapeutic Impact

10.3390/medicina61091619 · doi-reference

Gas6/AXL pathway: immunological landscape and therapeutic potential

10.3389/fonc.2023.1121130 · doi-reference

AXL Receptor Tyrosine Kinase as a Promising Therapeutic Target Directing Multiple Aspects of Cancer Progression and Metastasis

10.3390/cancers14030466 · doi-reference

AXL signaling in cancer: from molecular insights to targeted therapies

10.1038/s41392-024-02121-7 · doi-reference

Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer

10.1016/j.lungcan.2023.107291 · doi-reference

AXL kinase as a novel target for cancer therapy

10.18632/oncotarget.2542 · doi-reference

AXL in cancer: a modulator of drug resistance and therapeutic target

10.1186/s13046-023-02726-w · doi-reference

IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy

10.1186/s40364-022-00394-0 · doi-reference

Blockade of V-domain immunoglobulin suppressor of T-cell activation reprograms tumour-associated macrophages and improves efficacy of PD-1 inhibitor in gastric cancer

10.1002/ctm2.1578 · doi-reference

VISTA expression and patient selection for immune-based anticancer therapy

10.3389/fimmu.2023.1086102 · doi-reference

FOXD3 Regulates VISTA Expression in Melanoma

10.1016/j.celrep.2019.12.036 · doi-reference

Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors

10.1007/s00262-018-2227-8 · doi-reference

VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance

10.1126/science.aay0524 · doi-reference

VISTA-mediated immune evasion in cancer

10.1038/s12276-024-01336-6 · doi-reference

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

10.1016/s0140-6736(10)61121-x · doi-reference

Targeted Therapies and Developing Precision Medicine in Gastric Cancer

10.3390/cancers15123248 · doi-reference

IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer

10.1016/j.ccr.2009.01.001 · doi-reference

IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3

10.4049/jimmunol.1002971 · doi-reference

Tying the knot between cytokine and toll-like receptor signaling in gastrointestinal tract cancers

10.1111/cas.12205 · doi-reference

Helicobacter pylori-Mediated Immunity and Signaling Transduction in Gastric Cancer

10.3390/jcm9113699 · doi-reference

Helicobacter pylori infection and the development of gastric cancer

10.1056/nejmoa001999 · doi-reference